Upcycled Pharma

Upcycled Pharma is a Danish biotechnology company focused on repurposing and reformulating existing drugs to treat rare and orphan diseases. The company employs a proprietary upcycling strategy to identify approved molecules with untapped potential, aiming to deliver improved therapeutic outcomes with reduced clinical risk. Its lead program, UCP-001, is an oral small molecule inhibitor of plasma kallikrein currently in clinical development for the prevention of Hereditary Angioedema (HAE) attacks. By optimizing delivery and dosage of known compounds, Upcycled Pharma seeks to provide patient-centric solutions for underserved medical populations. The company leverages regulatory pathways such as the 505(b)(2) to accelerate the time to market for its candidates.